Albireo`s Bylvay (Odevixibat) Approved In Europe
Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio
Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023
FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome
Ipsen may have a mysterious company to thank for its $952 million takeover of Albireo Pharma.
Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMA
– Dr. Craig Hopkinson, currently EVP of Research & Development and Chief Medical Officer at Alkermes, brings strong global orphan drug development expertise – Dr. Paul Streck, former Chief...
BOSTON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today...